Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702662 | Urologic Oncology: Seminars and Original Investigations | 2017 | 10 Pages |
Abstract
Changes in NLR levels could be predictive for prognosis in patients with mRCC treated with first-line and second-line targeted therapy. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model in the first-line and subsequent second-line setting.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nobuyuki M.D., Ph.D., Ryuichi M.D., Ph.D., Yota M.D., Keiichi M.D., Ph.D., Suguru M.D., Ph.D., Ayako M.D., Yujiro M.D., Yasumasa M.D., Masayuki M.D., Kent M.D., Ph.D., Shuji M.D., Ph.D., Ken M.D., Ph.D., Tetsuo M.D., Ph.D., Takeshi M.D., Tomohiko M.D.,